
Personalis Inc (PSNL) Stock Forecast & Price Target
Personalis Inc (PSNL) Analyst Ratings
Bulls say
Personalis Inc exhibited a notable increase in gross margin to 27.1% in 4Q24, reflecting a 50 basis point improvement year-over-year, primarily attributed to a favorable customer mix and significant growth in biopharma testing and services, which rose by 59% to $51 million in 2024. The company has also shown an uptick in clinical test volumes, with 1,441 NeXT Dx and NeXT Personal tests completed in 4Q24, marking a 53% increase compared to the prior quarter. Furthermore, the increase in revenue from minimal residual disease (MRD) testing, which grew over 50% in 2024, highlights strong demand in the market and reinforces the successful partnership between Personalis and Tempus.
Bears say
Personalis Inc. has experienced a decline in revenue, with fourth-quarter total revenues decreasing by 15% year-over-year to $16.8 million, which fell below both consensus expectations and the company's previous growth rates. Additionally, the company faces significant risks, including slower adoption rates of its new products, heightened competition within its market, and a marked decline in revenue from the VA MVP program, which dropped from $4.4 million in the preceding quarter to just $0.2 million. The outlook for future growth appears pessimistic, with projections for 2025 total revenues revised downward to $86.9 million, significantly lower than earlier estimates, reflecting weak performance in both biopharma and clinical diagnostics segments.
This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.
Personalis Inc (PSNL) Analyst Forecast & Price Prediction
Start investing in Personalis Inc (PSNL)
Order type
Buy in
Order amount
Est. shares
0 shares